Similarly, in prostate cancer, SB-225002 inhibited AKT phosphorylation, thereby blocking the PI3K signaling pathway, while also suppressing the secretion of bone sialoprotein and osteopontin, ultimately attenuating metastatic progression (Xu et al., 2018). This evidence concerns the gene SPP1 and prostate carcinoma.